Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Relapsed and refractory classical Hodgkin lymphoma, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Which patients in complete remission after immunotherapy salvage can safely skip transplantation is unproven.
Salvage for patients already exposed to brentuximab and PD-1 antibodies in first line is undefined.
Allogeneic transplant after PD-1 blockade carries a risk of severe graft-versus-host disease.
Cumulative cardiac and lung toxicity limits options in multiply treated patients.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
PFS 13.
A milestone in how this cancer is treated.
ORR 69%.
A milestone in how this cancer is treated.